CSTONE PHARMA-B (02616.HK): Clinical Data of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Selected for ESMO 2026, Two Rapid Oral Presentations Scheduled
NewTimeSpace News: CSTONE PHARMA-B (02616.HK) announced on 20 July that clinical data of its core asset CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, has been accepted by ESMO Congress 2026 for two rapid oral presentations covering Phase I/II trial results in advanced NSCLC and metastatic colorectal cancer patients. Updated full data will be unveiled at the Madrid conference held from 23 to 26 October 2026. The Company reminds investors of uncertainties in the clinical development and commercialization of CS2009.
NewTimeSpace News: On 20 July 2026, CSTONE PHARMA-B (02616.HK) released a voluntary announcement. Clinical research outcomes of CS2009, the Company’s core asset — a PD-1/VEGF/CTLA-4 trispecific antibody — have been selected for presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress via two rapid oral presentations, featuring Phase I/II clinical data of CS2009 in patients with advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC) respectively.
Relevant abstract titles have been published on the official ESMO website, with data cut-off date as of April 2026. The Group will present updated clinical trial findings onsite at the ESMO Congress hosted in Madrid, Spain, during 23–26 October 2026.
CS2009 is a self-developed first-in-class trispecific antibody by CSTONE PHARMA-B that simultaneously targets three therapeutic targets: PD-1, VEGF and CTLA-4. The Company cautions that there is no guarantee of successful development and commercialization of CS2009.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- CSTONE PHARMA-B(02616.HK): Enters Exclusive Commercialization Partnership with Arrotex for Sugemalimab in Australia and New Zealand
- CStone Pharma-B (02616.HK): CS5007 Global Phase I Trial Initiated, Approved by Australian HREC
- CSTONE PHARMA-B(02616.HK): Proposes Open-Market Share Repurchase of Up to 136.45 Million Shares
- ETF Financing Ranking | China Southern CSI 500 ETF (510500) had a net financing buy-in of CNY 133.61 million on Jul 20, ranked top among comparable funds
